Rapamycin Treatment for Activated Phosphoinositide 3-Kinase δ Syndrome
Status:
Recruiting
Trial end date:
2022-11-30
Target enrollment:
Participant gender:
Summary
The purpose of this proposed research is to evaluate the efficacy and safety of the rapamycin
therapy in patients with activated phosphoinositide 3-kinase δ syndrome (APDS).